Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 15/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 11/20 | 0.54 |
| ▸ | ABL1 | P00519 | 8/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075954 | 0.95 | BRAF (0.55) | DDR2DDR1KITBRAF | |
| SCHEMBL1079653 | 0.93 | DDR2 (0.51) | DDR2DDR1ABL1RETBRAF | |
| SCHEMBL1149206 | 0.87 | EGFR (0.63) | ABL1KITRETBRAFSRC | |
| SCHEMBL13219897 | 0.85 | DDR2 (0.68) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL1078646 | 0.82 | LCK (0.51) | BRAFSRC | |
| SCHEMBL1078530 | 0.82 | DDR2 (0.56) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL13349275 | 0.82 | DDR2 (0.73) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL31620772 | 0.81 | DDR2 (0.72) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL5498924 | 0.81 | DDR2 (0.72) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL1078917 | 0.80 | ABL1 (0.58) | ABL1KITBRAFSRCBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269993-B1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269993-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039845-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | H1-2, H1-3, H1-0 | DDR2 2179/4885DDR1 4042/4885ABL1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.